Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
COMT inhibitor
Parkinson's disease
entacapone
healthcare resource usage (HCRU)
opicapone
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
13
07
2023
received:
30
05
2023
accepted:
20
07
2023
medline:
8
9
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
Motor fluctuations are a significant driver of healthcare resource utilization (HCRU) in people with Parkinson's disease (pwPD). A common management strategy is to include catechol-O-methyltransferase (COMT) inhibition with either opicapone or entacapone in the levodopa regimen. However, to date, there has been a lack of head-to-head data comparing the two COMT inhibitors in real-world settings. The aim of this study was to evaluate changes in HCRU and effect on sleep medications when opicapone was initiated as first COMT inhibitor versus entacapone. In this retrospective cohort study, we assessed HCRU outcomes in pwPD naïve to COMT inhibition via UK electronic healthcare records (Clinical Practice Research Datalink and Hospital Episodes Statistics databases, June 2016 to December 2019). HCRU outcomes were assessed before (baseline) and after COMT inhibitor prescription at 0-6 months, 7-12 months and 13-18 months. Opicapone-treated pwPD were algorithm-matched (1:4) to entacapone-treated pwPD. By 6 months, treatment with opicapone resulted in 18.5% fewer neurology outpatient visits compared to entacapone treatment; this effect was maintained until the last follow-up (18 months). In the opicapone group, the mean levodopa equivalent daily dose decreased over the first year and then stabilized, whereas the entacapone-treated group showed an initial decrease in the first 6 months followed by a dose increase between 7 and 18 months. Neither COMT inhibitor had a significant impact on sleep medication use. This head-to-head study is the first to demonstrate, using 'real-world' data, that initiating COMT inhibition with opicapone is likely to decrease the need for post-treatment HCRU versus initiation of COMT inhibition with entacapone.
Sections du résumé
BACKGROUND AND PURPOSE
Motor fluctuations are a significant driver of healthcare resource utilization (HCRU) in people with Parkinson's disease (pwPD). A common management strategy is to include catechol-O-methyltransferase (COMT) inhibition with either opicapone or entacapone in the levodopa regimen. However, to date, there has been a lack of head-to-head data comparing the two COMT inhibitors in real-world settings. The aim of this study was to evaluate changes in HCRU and effect on sleep medications when opicapone was initiated as first COMT inhibitor versus entacapone.
METHODS
In this retrospective cohort study, we assessed HCRU outcomes in pwPD naïve to COMT inhibition via UK electronic healthcare records (Clinical Practice Research Datalink and Hospital Episodes Statistics databases, June 2016 to December 2019). HCRU outcomes were assessed before (baseline) and after COMT inhibitor prescription at 0-6 months, 7-12 months and 13-18 months. Opicapone-treated pwPD were algorithm-matched (1:4) to entacapone-treated pwPD.
RESULTS
By 6 months, treatment with opicapone resulted in 18.5% fewer neurology outpatient visits compared to entacapone treatment; this effect was maintained until the last follow-up (18 months). In the opicapone group, the mean levodopa equivalent daily dose decreased over the first year and then stabilized, whereas the entacapone-treated group showed an initial decrease in the first 6 months followed by a dose increase between 7 and 18 months. Neither COMT inhibitor had a significant impact on sleep medication use.
CONCLUSIONS
This head-to-head study is the first to demonstrate, using 'real-world' data, that initiating COMT inhibition with opicapone is likely to decrease the need for post-treatment HCRU versus initiation of COMT inhibition with entacapone.
Substances chimiques
Antiparkinson Agents
0
Catechol O-Methyltransferase
EC 2.1.1.6
Catechol O-Methyltransferase Inhibitors
0
COMT protein, human
EC 2.1.1.6
entacapone
4975G9NM6T
Levodopa
46627O600J
opicapone
Y5929UIJ5N
Oxadiazoles
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3132-3141Informations de copyright
© 2023 Bial Portela and The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Mizuno Y, Shimoda S, Origasa H. Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs. J Neural Transm (Vienna). 2018;125:35-43.
Kim HJ, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH. Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord. 2020;35:185-190.
Hauser RA, McDermott MP, Messing S, Group ftPS. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63:1756-1760.
Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol. 2010;63:257-266.
Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726-733.
Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20:S11-S16.
Rodriguez-Blazquez C, Schrag A, Rizos A, Chaudhuri KR, Martinez-Martin P, Weintraub D. Prevalence of non-motor symptoms and non-motor fluctuations in Parkinson's disease using the MDS-NMS. Mov Disord Clin Pract. 2021;8:231-239.
Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson's disease. Age Ageing. 2006;35:220-228.
Müller T. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Drugs. 2015;75:157-174.
Ferreira JJ, Poewe W, Rascol O, et al. Effect of Opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson's disease. Mov Disord. 2022;37:2272-2283.
Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013;20:5-15.
Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154-165.
Ferreira JJ, Lees AJ, Poewe W, et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology. 2018;90:e1849-e1857.
Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol. 2017;46:1093-1093i.
Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827-836.
MHRA. Clinical Practice Research Datalink. https://cprd.com
NHS digital. Hospital Episode Statistics (HES). Last accessed July 2023. https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics/how-we-collect-and-process-hospital-episode-statistics-hes-data
https://cprd.com/protocol/effectiveness-opicapone-treatment-compared-entacapone-parkinsons-disease-using-electronic
Gungabissoon U, Kirichek O, El Baou C, Galwey N. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. Pharmacoepidemiol Drug Saf. 2020;29:591-598.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25:2649-2653.
NICE. Parkinson's disease with end-of-dose motor fluctuations: opicapone. Evidence summary ES9. Last accessed July 2023. Available from: https://www.nice.org.uk/advice/es9 2017.
South East London Area Prescribing Committee Formulary recommendation. Last accessed July 2023. Available from: https://selondonccg.nhs.uk/wp-content/uploads/dlm_uploads/2021/09/Recommendation-087-Opicapone-in-Parkinsons-Disease-July-2018.pdf?UNLID=418181178202219175258
Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004;2004:Cd004554.
Lees A, Ferreira JJ, Rocha JF, et al. Safety profile of Opicapone in the Management of Parkinson's disease. J Parkinsons Dis. 2019;9:733-740.
Reichmann H, Lees A, Rocha JF, Magalhaes D, Soares-da-Silva P, OPTIPARK investigators. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:9.
Larsen JP, Worm-Petersen J, Siden A, et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol. 2003;10:137-146.
Ahn TB, Im JH, Lee MC, Kim JW, Lee WY, Jeon BS. One-year open-label study of entacapone in patients with advanced Parkinson disease. J Clin Neurol. 2007;3:82-85.
Schofield C, Chaudhuri KR, Carroll C, et al. Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegener Dis Manag. 2022;12:77-91.
Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord. 2005;20:1104-1108.
Muzerengi S, Herd C, Rick C, Clarke CE. A systematic review of interventions to reduce hospitalisation in Parkinson's disease. Parkinsonism Relat Disord. 2016;24:3-7.
Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197-206.
Park KW, Jo S, Lee SH, et al. Therapeutic effect of levodopa/carbidopa/Entacapone on sleep disturbance in patients with Parkinson's disease. J Mov Disord. 2020;13:205-212.
Stacy M. Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging. 2002;19:733-739.
Parkinson's Excellence Network. 2022 UK Parkinson's Audit. Summary Report. 2022 https://www.parkinsons.org.uk/sites/default/files/2023-06/2022%20Summary%20Report%20-%20FINAL.pdf
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107.